MedPath

Uprosertib

Generic Name
Uprosertib
Drug Type
Small Molecule
Chemical Formula
C18H16Cl2F2N4O2
CAS Number
1047634-65-0
Unique Ingredient Identifier
ZXM835LQ5E
Background

Uprosertib has been used in trials studying the treatment of Cancer, Melanoma, Solid Tumours, Cervical Cancer, and HER2/Neu Negative, among others.

Clinical Trials
Related News

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2
Completed
Conditions
Refractory Plasma Cell Myeloma
Recurrent Plasma Cell Myeloma
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2013-11-21
Last Posted Date
2022-03-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
25
Registration Number
NCT01989598
Locations
πŸ‡¨πŸ‡¦

University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

πŸ‡¨πŸ‡¦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

πŸ‡¨πŸ‡¦

Cross Cancer Institute, Edmonton, Alberta, Canada

and more 2 locations

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Phase 2
Completed
Conditions
Recurrent Uveal Melanoma
Stage IV Uveal Melanoma AJCC v7
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2013-11-08
Last Posted Date
2020-02-24
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT01979523
Locations
πŸ‡ΊπŸ‡Έ

M D Anderson Cancer Center, Houston, Texas, United States

πŸ‡«πŸ‡·

Institut Curie Paris, Paris, France

πŸ‡ΊπŸ‡Έ

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

GSK1120212+GSK2141795 for Cervical Cancer

Phase 2
Terminated
Conditions
Cervical Cancer
Interventions
Drug: GSK1120212 (trametinib)
First Posted Date
2013-10-08
Last Posted Date
2019-05-31
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
14
Registration Number
NCT01958112
Locations
πŸ‡ΊπŸ‡Έ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
First Posted Date
2013-09-13
Last Posted Date
2020-02-12
Lead Sponsor
Adil Daud
Target Recruit Count
20
Registration Number
NCT01941927
Locations
πŸ‡ΊπŸ‡Έ

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

πŸ‡ΊπŸ‡Έ

University of California, San Francisco, San Francisco, California, United States

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 1
Completed
Conditions
Endometrial Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Endometrial Serous Adenocarcinoma
Recurrent Uterine Corpus Cancer
Interventions
Other: Laboratory Biomarker Analysis
First Posted Date
2013-09-05
Last Posted Date
2020-10-14
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
26
Registration Number
NCT01935973
Locations
πŸ‡ΊπŸ‡Έ

University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

πŸ‡ΊπŸ‡Έ

University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

πŸ‡ΊπŸ‡Έ

Washington University School of Medicine, Saint Louis, Missouri, United States

and more 19 locations

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase 1
Completed
Conditions
Unresectable Malignant Solid Neoplasm
Unresectable Melanoma
Locally Advanced Malignant Solid Neoplasm
Locally Advanced Melanoma
Metastatic Malignant Solid Neoplasm
Stage IIIC Cutaneous Melanoma AJCC v7
Hematopoietic and Lymphoid Cell Neoplasm
Metastatic Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
First Posted Date
2013-07-18
Last Posted Date
2025-01-14
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
27
Registration Number
NCT01902173
Locations
πŸ‡ΊπŸ‡Έ

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

πŸ‡ΊπŸ‡Έ

Clackamas Radiation Oncology Center, Clackamas, Oregon, United States

and more 13 locations

An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer

Phase 1
Completed
Conditions
Solid Tumours
Interventions
First Posted Date
2010-12-24
Last Posted Date
2017-11-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
36
Registration Number
NCT01266954
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, London, United Kingdom

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Phase 1
Completed
Conditions
Cancer
Interventions
First Posted Date
2010-06-07
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
240
Registration Number
NCT01138085
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Salt Lake City, Utah, United States

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

Phase 1
Completed
Conditions
Cancer
Interventions
First Posted Date
2009-06-15
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
77
Registration Number
NCT00920257
Locations
πŸ‡¨πŸ‡¦

GSK Investigational Site, Toronto, Ontario, Canada

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy